Improving Beta Cell Function in Mexican American Women With Prediabetes

NCT02488057 on ClinicalTrials.gov · last registry update 2019-08-28

An unusually large phase 4: 360 participants, more than double the 75 typical for the stage. The sponsor logged completion for March 2019. Primary outcome, as filed: Beta Cell Function. liraglutide is approved in the US, but not for prediabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Ohio State University
Sponsor type: Other
Enrollment: 360
Started: 2016-05
Primary completion: 2019-03 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Beta Cell Function

Conditions studied

Pre-Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.